Publications by authors named "Alamgir Sattar"
Article Synopsis
- - Despite advancements in insulin treatments and monitoring, only 20% of type 1 diabetes patients achieve good control, highlighting a clear need for better options.
- - Pramlintide is the only approved adjunct therapy for type 1 diabetes, but global trials are evaluating other medications like liraglutide, dapagliflozin, and sotagliflozin for potential use.
- - Dapagliflozin and sotagliflozin show benefits such as lower HbA1c levels and reduced glycemic fluctuations, though they're not yet available in the U.S. due to safety concerns; meanwhile, new trials with a combination therapy of semaglutide and dapagliflozin are ongoing.
Unlabelled:
Objective::
Background:: Rhabdomyolysis is a syndrome characterized by skeletal muscle breakdown, that involves the release of intracellular contents into the circulation, including creatine kinase (CK), myoglobin, electrolytes, organic acids, and purines. Causes of rhabdomyolysis include trauma, exertion, drugs, and toxins (including alcohol), and electrolyte abnormalities. The treatment of rhabdomyolysis is to remove the cause and use intravenous (IV) fluids.
BACKGROUND Thrombotic thrombocytopenic purpura (TTP) is one of the thrombotic microangiopathic (TMA) syndromes, caused by severely reduced activity of the vWF-cleaving protease ADAMTS13. Systemic lupus erythematosus (SLE), on the other hand, is an autoimmune disease that affects various organs in the body, including the hematopoietic system. SLE can present with TMA, and differentiating between SLE and TTP in those cases can be very challenging, particularly in patients with no prior history of SLE.
View Article and Find Full Text PDF